TrialThe Lancet. Infectious diseases2022

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.

Raburn M Mallory et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.